Cellectar Biosciences Inc
NASDAQ:CLRB
Cellectar Biosciences Inc
NASDAQ:CLRB
Price:
2.76
USD
-2.13%
Market Closed
Market Cap:
$11.7m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Cellectar Biosciences Inc
NASDAQ:CLRB
|
US |
|
S
|
SPX Technologies Inc
F:SPW0
|
US |
|
Huaren Pharmaceutical Co Ltd
SZSE:300110
|
CN |
|
H
|
Helium Evolution Inc
XTSX:HEVI
|
CA |
|
S
|
Stalprodukt SA
WSE:STP
|
PL |
|
Focusrite PLC
LSE:TUNE
|
UK |
|
Kesko Oyj
OMXH:KESKOB
|
FI |
|
V
|
Viglacera Tien Son JSC
VN:VIT
|
VN |
|
H
|
HMM Co Ltd
KRX:011200
|
KR |
|
L
|
Luolai Lifestyle Technology Co Ltd
SZSE:002293
|
CN |
|
P
|
Prince Pipes and Fittings Ltd
NSE:PRINCEPIPE
|
IN |
Balance Sheet
Balance Sheet Decomposition
Cellectar Biosciences Inc
Cellectar Biosciences Inc
Balance Sheet Decomposition is not available for
Cellectar Biosciences Inc
Cellectar Biosciences Inc
Balance Sheet
Cellectar Biosciences Inc
Cellectar Biosciences Inc
Currency: USD
| Dec-2007 | Dec-2008 | Dec-2009 | Dec-2010 | Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash & Cash Equivalents |
10
|
1
|
9
|
1
|
6
|
5
|
2
|
9
|
4
|
11
|
10
|
13
|
11
|
57
|
36
|
20
|
10
|
23
|
13
|
|
| Cash Equivalents |
10
|
1
|
9
|
1
|
6
|
5
|
2
|
9
|
4
|
11
|
10
|
13
|
11
|
57
|
36
|
20
|
10
|
23
|
13
|
|
| Other Current Assets |
1
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Total Current Assets |
11
|
1
|
9
|
1
|
6
|
5
|
3
|
10
|
4
|
12
|
10
|
14
|
11
|
58
|
37
|
21
|
10
|
24
|
14
|
|
| PP&E Net |
0
|
0
|
0
|
4
|
3
|
3
|
2
|
2
|
2
|
1
|
0
|
1
|
1
|
1
|
1
|
1
|
2
|
1
|
1
|
|
| PP&E Gross |
0
|
0
|
0
|
4
|
3
|
3
|
2
|
0
|
2
|
1
|
0
|
0
|
1
|
1
|
1
|
1
|
2
|
1
|
1
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
2
|
2
|
3
|
3
|
0
|
4
|
4
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
|
| Goodwill |
0
|
0
|
0
|
0
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Assets |
0
|
0
|
0
|
0
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
11
N/A
|
1
-87%
|
9
+507%
|
5
-46%
|
11
+120%
|
11
+9%
|
7
-41%
|
13
+97%
|
8
-43%
|
15
+102%
|
13
-16%
|
15
+17%
|
12
-19%
|
59
+379%
|
37
-37%
|
22
-42%
|
12
-44%
|
25
+111%
|
15
-41%
|
|
| Liabilities | ||||||||||||||||||||
| Accounts Payable |
6
|
5
|
3
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
2
|
2
|
2
|
2
|
3
|
4
|
7
|
5
|
3
|
|
| Accrued Liabilities |
1
|
2
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
2
|
2
|
2
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
11
|
0
|
0
|
0
|
3
|
5
|
5
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
2
|
0
|
|
| Total Current Liabilities |
7
|
7
|
17
|
1
|
1
|
1
|
5
|
6
|
6
|
2
|
2
|
2
|
3
|
4
|
4
|
6
|
13
|
9
|
5
|
|
| Long-Term Debt |
0
|
0
|
0
|
4
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
|
| Total Liabilities |
7
N/A
|
7
0%
|
17
+146%
|
5
-73%
|
1
-77%
|
1
+22%
|
5
+288%
|
7
+31%
|
6
-11%
|
2
-70%
|
2
+19%
|
2
-16%
|
3
+78%
|
4
+21%
|
4
+8%
|
6
+46%
|
13
+121%
|
10
-27%
|
5
-48%
|
|
| Equity | ||||||||||||||||||||
| Common Stock |
10
|
14
|
18
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
3
|
1
|
20
|
1
|
1
|
6
|
2
|
2
|
|
| Retained Earnings |
43
|
60
|
76
|
24
|
31
|
40
|
51
|
59
|
65
|
71
|
84
|
98
|
112
|
127
|
151
|
180
|
217
|
247
|
269
|
|
| Additional Paid In Capital |
37
|
40
|
49
|
24
|
41
|
50
|
53
|
66
|
66
|
83
|
94
|
108
|
120
|
162
|
183
|
194
|
210
|
261
|
277
|
|
| Total Equity |
4
N/A
|
6
N/A
|
8
-51%
|
0
N/A
|
9
+7 192%
|
10
+7%
|
2
-83%
|
7
+294%
|
2
-75%
|
14
+721%
|
11
-21%
|
13
+23%
|
9
-32%
|
55
+505%
|
33
-40%
|
16
-53%
|
1
N/A
|
16
N/A
|
10
-37%
|
|
| Total Liabilities & Equity |
11
N/A
|
1
-87%
|
9
+507%
|
5
-46%
|
11
+120%
|
11
+9%
|
7
-41%
|
13
+97%
|
8
-43%
|
15
+102%
|
13
-16%
|
15
+17%
|
12
-19%
|
59
+379%
|
37
-37%
|
22
-42%
|
12
-44%
|
25
+111%
|
15
-41%
|
|
| Shares Outstanding | ||||||||||||||||||||
| Common Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
4
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Switch to:
Switch to:
See Also
Discover More
